UBS Raises price Target on Foundation Medicine (FMI) to $22

September 21, 2016 9:33 AM EDT
Get Alerts FMI Hot Sheet
Price: $18.60 +2.48%

Rating Summary:
    2 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade FMI Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

UBS reiterated a Neutral rating on Foundation Medicine (NASDAQ: FMI), and raised the price target to $22.00 (from $16.00), following the company's announced expanded Local Coverage Determination.

Analyst Jonathan Groberg commented, "Palmetto, a Medicare contractor, announced last Thursday an expanded Local Coverage Determination (LCD) to include all stage IIIB/IV non-small cell lung cancer (NSCLC) patients. This new policy now provides coverage for comprehensive genomic profiling (CGP) for metastatic NSCLC patients who have not been tested for genomic mutations or who have tested negative for EGFR mutations. This is important for patients as CGP detected alterations may indicate eligibility for targeted treatment or immunotherapy."

For an analyst ratings summary and ratings history on Foundation Medicine click here. For more ratings news on Foundation Medicine click here.

Shares of Foundation Medicine closed at $23.60 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities


Add Your Comment